Global Access

Type 1 Diabetes (T1D) is a complex chronic disease that requires consistent access to insulin, syringes, and blood glucose monitors. This can be a challenge anywhere, and one that is particularly acute across many low- and middle-income countries (LMICs), where health systems often lack the resources for comprehensive diabetes care. T1D can be a death sentence for those who cannot afford insulin, while others may not receive proper care until they develop life-threatening complications, such as diabetic ketoacidosis (DKA). Children are at particular risk.

Helmsley recognizes that barriers to care are deeply entrenched. Our goal is to create a sustainable, global movement that improves policies, supply chains, and health systems for the most vulnerable T1D populations in LMICs, where – as elsewhere – type 2 diabetes is far more common.

Internationally, new cases are skyrocketing. From 2009 to 2019, the number of people worldwide diagnosed with diabetes, type 1 and type 2, increased 62 percent, to 463 million, according to Diabetes Research and Clinical Practice. By 2045, the number is projected to be 629 million.

This surge is felt most acutely in LMICs, which often lack the clinics, diagnostic tools, medical specialists, educators, distribution networks, and government support to give people with T1D an opportunity for success. In some countries, T1D carries a stigma – mothers are blamed for their child’s condition and are spurned by their community, while the children themselves become pariahs. Meanwhile, the increase in type 2 cases will lead to greater need for wide distribution and availability of insulin.

Our Global Access program focuses on three main areas:

First, health systems need to be stronger so that they can care for anyone with a chronic illness, including T1D. According to the World Health Organization (WHO), at least half of the world’s population still lacks access to essential health services for non-communicable diseases (NCDs), so we work with partners addressing this need. This includes expanding  PEN-Plus (the Package of Essential NCD Interventions-Plus), an integrated delivery model that provides high-quality care for T1D and other severe chronic NCDs in low-resource countries. We anticipate that more than 20 countries will be part of a network committed to expanded treatment for T1D and other severe chronic diseases, and four of these countries will implement PEN-Plus nationwide.

We are also galvanizing a global movement, through partnerships with groups like the NCD Alliance, to advocate for the needs of the growing number of people living with chronic conditions in LMICs.

Second, we want to improve access to insulin, which is unaffordable for most people living in LMICs. We work on two timelines – addressing the medium-term need of changing multinational pricing and supply chain practices, while also ensuring that children who need insulin today can get it. We have supported Health Action International, a nonprofit, to develop partnerships with the WHO and to support civil society organizations in Peru, Mali, and Tanzania to advocate for better insulin pricing and diabetes policies globally. We also support efforts to distribute insulin and supplies across poor communities in more than 40 countries.

Third, we recognize that health care is but one part of what is needed to be healthy. Food security is essential. In impoverished communities, our approach to supporting the T1D community is holistic, supporting efforts for sustainable livelihoods and economic development.

“The basic supplies required to live with type 1 diabetes are relatively simple and inexpensive to manufacture, yet people are dying because they cannot access them. We must work together to put an end to this.”

News & Insights
}

Published Thu Nov 18, 2021

PATH and the Helmsley Charitable Trust Partner to Improve Access to Safe Administration Of Insulin and High-Quality Self-Care for People Living with Diabetes

Seattle, WA and New York, NY, November 19, 2021 – A century after the life-changing discovery of insulin, ...

NCD Short Film Wins at WHO Film Festival


Living Without Limits, featuring Helmsley grantee Life for a Child, has won best NCD short ...

African WHO Ministers Adopt PEN-Plus, an Innovative Measure to Contain Noncommunicable Diseases

This year, while gathered at the 72nd Session of the WHO Regional Committee for Africa...
African WHO Ministers Adopt PEN-Plus, an Innovative Measure to Contain Noncommunicable Diseases

The Helmsley Charitable Trust Partners with AMP Health to Accelerate Progress against Non-Communicable Diseases in Africa

The Leona M. and Harry B. Helmsley Charitable Trust today announced a new $3 million,...
The Helmsley Charitable Trust Partners with AMP Health to Accelerate Progress against Non-Communicable Diseases in Africa

Op-Ed: Lessons from Diabetes Can Strengthen Global Care for People with NCDs

Gina Agiostratidou, PhD, Director of the Type 1 Diabetes Program, published an op-ed in Devex...
Op-Ed: Lessons from Diabetes Can Strengthen Global Care for People with NCDs

Gina Agiostratidou, PhD Quoted in Coverage of the Lancet NCDI Poverty Commission

Gina Agiostratidou, PhD, Type 1 Diabetes Program Director, was quoted in coverage of the Helmsley-supported...
Gina Agiostratidou, PhD Quoted in Coverage of the Lancet NCDI Poverty Commission

Forgotten Diseases Hit Poorest Billion Hardest during Pandemic

A new Lancet Commission report shows for the first time that non-communicable diseases and injuries...
Forgotten Diseases Hit Poorest Billion Hardest during Pandemic
}

Published Thu Aug 13, 2020

Helmsley Joins Coalition to Improve Access to Medicines and Products for People Living with NCDs in Low- & Middle-Income Countries

The Leona M. and Harry B. Helmsley Charitable Trust and the Coalition for Access to ...
}

Published Wed Feb 12, 2020

NCD Alliance and Helmsley Charitable Trust Partner to Improve Care for People Living with Chronic NCDs in Low- and Middle-Income Countries

Today, the NCD Alliance and The Leona M. and Harry B. Helmsley Charitable Trust announced ...